MedPath
Found 374 clinical trials|View Analysis
Sort by:

Clinical Trial Evaluating Safety of 5-Aminolevulinic Acid (5-ALA) Combined with CV01 Delivery of Ultrasound for Sonodynamic Therapy (SDT) in Patients with Newly Diagnosed High-Grade Glioma (HGG) Prior to Resection and Standard Adjuvant Therapy (ALA SDT GLIOMA 401)

Phase 1
Not yet recruiting
Conditions
Anaplastic Astrocytoma (AA)
Anaplastic Oligodendroglioma (AO)
Glioblastoma (GBM)
Interventions
Drug: 5-Aminolevulinic acid Hydrochloride (Gliolan®)
Device: CV01
First Posted Date
2024-10-30
Last Posted Date
2024-11-08
Lead Sponsor
Universität Münster
Target Recruit Count
14
Registration Number
NCT06665724
Locations
🇩🇪

Department of Neurosurgery, University Hospital Münster, Münster, Germany

5G-EMERALD: Amivantamab in Malignant Brain Tumours

Phase 1
Recruiting
Conditions
Malignant Primary Gliomas
Glioblastoma Multiform (Grade IV Astrocytoma)
Diffuse Hemispheric Glioma, H3 G34-Mutant
Glioblastoma Multiforme (GBM)
Interventions
First Posted Date
2024-10-09
Last Posted Date
2024-11-06
Lead Sponsor
Institute of Cancer Research, United Kingdom
Target Recruit Count
12
Registration Number
NCT06632236
Locations
🇬🇧

Cambridge University Hospitals, Cambridge, United Kingdom

🇬🇧

The Royal Marsden Hospital - Drug Development Unit, Sutton, United Kingdom

5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours

Phase 1
Recruiting
Conditions
Glioblastoma Multiforme (GBM)
Glioblastoma Multiform (Grade IV Astrocytoma)
Diffuse Hemispheric Glioma, H3 G34-Mutant
Malignant Primary Gliomas
Interventions
First Posted Date
2024-10-08
Last Posted Date
2024-11-07
Lead Sponsor
Institute of Cancer Research, United Kingdom
Target Recruit Count
182
Registration Number
NCT06630260
Locations
🇬🇧

Cambridge University Hospitals, Cambridge, United Kingdom

🇬🇧

The Royal Marsden Hospital - Drug Development Unit, Sutton, United Kingdom

🇬🇧

The Royal Marsden Hospital - Neuro-Oncology Unit, Sutton, United Kingdom

Comparing Telehealth and In-person Assessments in Glioma Patients Receiving Oral Chemotherapy

Phase 4
Recruiting
Conditions
Astrocytoma, IDH-Mutant
Glioblastoma
Glioma
Oligodendroglioma, IDH-Mutant and 1p/19q-Codeleted
Interventions
Behavioral: Assessment
Other: Questionnaire Administration
Other: Telemedicine Visit
Drug: Temozolomide
First Posted Date
2024-10-03
Last Posted Date
2024-10-21
Lead Sponsor
Mayo Clinic
Target Recruit Count
30
Registration Number
NCT06625047
Locations
🇺🇸

Mayo Clinic in Rochester, Rochester, Minnesota, United States

Extensive Resection of Malignant Brain Tumors Using Advanced Imaging Techniques

Not Applicable
Recruiting
Conditions
Glioblastoma
Astrocytoma, IDH-Mutant, Grade 4
Interventions
Procedure: Multimodal image-guided resection
First Posted Date
2024-10-02
Last Posted Date
2024-10-02
Lead Sponsor
Amsterdam UMC, location VUmc
Target Recruit Count
30
Registration Number
NCT06623565
Locations
🇳🇱

Amsterdam UMC location VUmc, Amsterdam, Noord Holland, Netherlands

Impact of IDH Mutation and Adjuvant Chemo(radio)therapy on Survival Outcome in Grade II/III Astrocytoma

Completed
Conditions
Astrocytoma
Astrocytic Tumors
Astrocytoma of Brain
Interventions
Other: IDH mutant-type
Other: IDH wild-type
First Posted Date
2024-10-01
Last Posted Date
2024-10-29
Lead Sponsor
asmaa salama ibrahim
Target Recruit Count
811
Registration Number
NCT06620926
Locations
🇪🇬

Suez Canal University, Ismailia, Egypt

A Phase IB 2 Dose Trial of IRS-1 HSV C134 (IND 17296) Administered Intratumorally in Patients with Recurrent Malignant Glioma

Phase 1
Not yet recruiting
Conditions
Glioblastoma
Glioblastoma (GBM)
Astrocytoma
Astrocytoma, Grade III
Astrocytoma, Grade IV
Gliosarcoma, Adult
Gliosarcoma of Brain
Interventions
First Posted Date
2024-09-26
Last Posted Date
2024-10-24
Lead Sponsor
James Markert, MD
Target Recruit Count
12
Registration Number
NCT06614855
Locations
🇺🇸

The University of Alabama at Birmingham Hospital, Birmingham, Alabama, United States

CBT-I in Primary Brain Tumor Patients: Phase IIc Randomized Feasibility Pilot Trial

Phase 2
Recruiting
Conditions
Primary Brain Tumor
Astrocytoma
Oligodendroglioma
Primary Central Nervous System (CNS) Lymphoma
Meningioma
Glioblastoma
Interventions
Behavioral: Cognitive Behavioral Therapy for Insomnia
First Posted Date
2024-06-03
Last Posted Date
2024-07-10
Lead Sponsor
Virginia Commonwealth University
Target Recruit Count
60
Registration Number
NCT06439420
Locations
🇺🇸

Virginia Commonwealth University, Richmond, Virginia, United States

Hypofractionation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma

Phase 1
Recruiting
Conditions
Astrocytoma
Glioma
Recurrent Glioblastoma
Interventions
Radiation: Radiation Therapy
First Posted Date
2024-04-03
Last Posted Date
2024-12-27
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
28
Registration Number
NCT06344130
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion

Early Phase 1
Not yet recruiting
Conditions
Glioblastoma Multiforme
WHO Grade IV Glioma
Diffuse Midline Glioma, H3K27-altered
High Grade Glioma
Diffuse Intrinsic Pontine Glioma
Infant Type Hemispheric Glioma
Anaplastic Astrocytoma
Glioblastoma
WHO Grade III Glioma
Interventions
First Posted Date
2024-03-27
Last Posted Date
2024-03-27
Lead Sponsor
Nationwide Children's Hospital
Target Recruit Count
15
Registration Number
NCT06333899
Locations
🇺🇸

Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States

🇺🇸

Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States

🇺🇸

Texas Children's Hospital, Houston, Texas, United States

and more 14 locations
© Copyright 2025. All Rights Reserved by MedPath